Pfizer Inc (PFE.N)
23 Feb 2018
Fri, Feb 23 2018
* PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF®
* PFIZER INC - BOURLA IS CURRENTLY COO OF PFIZER Source text for Eikon: Further company coverage:
* SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING
* RECKITT BENCKISER CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTH AUCTION
FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.
FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.
* CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS
BRIEF-Pfizer Receives Breakthrough Therapy Designation From FDA For Atopic Dermatitis Treatment, PF-04965842
* PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-04965842, AN ORAL JAK1 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Source text for Eikon: Further company coverage:
NEW YORK A Long Island, New York, investment adviser was sentenced to six months in prison on Monday after he pleaded guilty to insider trading in connection with Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc.
* NETVATION DL MEDICINE -ENTERED INTO A TWO-YEAR RESEARCH COLLABORATION WITH PFIZER INC
- Arcus Biosciences Files To Raise $100 Million In IPO
- IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield
- Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement
- Corium International: Will This Stellar Growth Company Continue To Deliver Profits?
- Biotechs: Still Well Placed For More Gains
- 2018 Brings New Challenges And Opportunities For Alnylam Pharmaceuticals